Microglia have been revealed to first help spread Alzheimer’s disease pathology across the brain and then activate to limit ...

The first pill to slow down the progression of Alzheimer’s disease is being studied for use on the NHS. Regulators are due to ...

Researchers with the Advanced Science Research Center at the CUNY Graduate Center (CUNY ASRC) have unveiled a critical ...

Althea Jordan sits in her white recliner while her physical therapist, Danielle Heltzel, kneels on the floor in front of her ...

Alzheimer's is the most common cause of dementia and researchers say their findings could lead to treatments that could slow ...

As the year comes to a close, experts from the Alzheimer's Association reflect on some of the hopeful advances in diagnosis, ...

CUNY scientists made a key Alzheimer's disease breakthrough, identifying a vital mechanism in the brain’s immune cells that ...

Researchers with the Advanced Science Research Center at the CUNY Graduate Center (CUNY ASRC) have unveiled a critical ...

The daily medication, called hydromethylthionine mesylate (HMTM), was developed by British firm TauRX in Aberdeen ...

Discover how stressed-out immune cells in the brain may be the key culprit behind the development of Alzheimer's disease.

ASN-90 is under clinical development by Asceneuron and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success ...